Synchron Valuation, Funding & Investors

Synchron is valued at $900M as of November 2025.

Last Synchron valuation

$900M

Series D · Nov 2025

Last Synchron funding round

$200M

Series D · Nov 2025

Cumulative funding Synchron raised

$325M

across 4 funding rounds

Key investors in Synchron

  • Neurotechnology Investors
  • Khosla Ventures
  • ARCH Venture Partners
  • METIS innovative
  • K5 Global
  • Qatar Investment Authority

Synchron Overview

About Synchron

Synchron is a neurotechnology company advancing brain-computer interfaces through its endovascular Stentrode device. Delivered via catheter to the brain's blood vessels, it records neural signals for controlling external devices like prosthetics and computers. Brooklyn-headquartered, Synchron conducts clinical trials in Australia and the United States targeting paralysis patients.


Founded

2016

HQ

United StatesNew York City, NY

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$900M (Nov 2025)

Synchron Valuation

Synchron is currently valued at $900M, based on its Series D in November 2025.

The $200M round was led by Double Point Ventures, with participation from K5 Global, Qatar Investment Authority, T.Rx Capital, Khosla Ventures, Protocol Labs and 6 other investors.

Synchron's valuation has grown 6.4x from $140M at its Series B in June 2021 to $900M in November 2025, across 3 priced rounds.

Synchron valuation by funding round

Synchron valuation by funding round
DateStageValuation
Nov 2025Series D$900M
Dec 2022Series C$401M
Jun 2021Series B$140M

Synchron Funding History

Synchron has raised a total of $325M across 4 funding rounds.

Synchron's first fundraising round was a $10M Series A in April 2017. The most recent completed round was a $200M Series D in November 2025.

Synchron funding rounds

Synchron funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Nov 2025Series DDouble Point Ventures (lead); K5 Global; Qatar Investment Authority; T.Rx Capital; Khosla Ventures; Protocol Labs; Neurotechnology Investors; Bezos Expeditions; METIS innovative; National Reconstruction Fund Corporation; IQT; ARCH Venture Partners$200M$900MSynchron, a New York-based neurotechnology company, develops the Stentrode brain-computer interface (BCI), a nonsurgical, endovascular implant designed for people with paralysis to translate brain activity into digital commands for everyday use. The Series D round on November 6-7, 2025, raised $200 million led by Double Point Ventures, with participation from existing investors ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, Neurotechnology Investors (NTI), and METIS Innovate, plus new investors including the Australian National Reconstruction Fund, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, and IQT. This brought total funding to $345 million. The proceeds will fund pivotal trials, commercial launch preparations for the first-generation Stentrode platform, expansion of a cognitive AI division in New York to train real-time thought-decoding models from brain data, and a new San Diego engineering hub for next-generation high-channel whole-brain interfaces. CEO Tom Oxley highlighted the funding's role in advancing commercialization and breakthrough BCI development. Double Point Ventures' Campbell Murray emphasized Synchron's scalable, minimally invasive approach combining neurovascular access, device engineering, and adaptive AI. The round signals strong investor confidence amid 2025 BCI investments exceeding $1 billion, positioning Synchron closest to regulatory approval for permanent market authorization (PMA). Prior milestones include a 2022 $75 million Series C backed by Gates, Bezos, and ARCH, safety data publications, executive team growth, manufacturing deals, and integrations with Apple, Amazon, OpenAI, and NVIDIA. A reported post-money valuation of about $1 billion underscores commercial potential in the evolving neurotech landscape.
Dec 2022Series CARCH Venture Partners (lead)$75M$401MSynchron is a clinical-stage endovascular brain-computer interface (BCI) company developing the Synchron Switch BCI, implanted via a minimally invasive jugular vein procedure in the motor cortex to treat paralysis and restore autonomy for patients with upper limb impairment, targeting a market of 100 million people worldwide. The company eliminates the need for open brain surgery, with positive long-term safety results from the SWITCH trial in Australia and FDA approval for the COMMAND pivotal trial in the US, including a historic implant at Mount Sinai in July 2022. On December 15, 2022, Synchron raised an oversubscribed $75 million Series C round led by ARCH Venture Partners, bringing total funding to $145 million since inception. New investors included Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X, with participation from existing backers like Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group, and University of Melbourne. ARCH's Ari Nowacek joined the board, and Robert Nelsen became a board observer. Proceeds fund acceleration of the Synchron Switch BCI platform, pivotal clinical trials, and path to first-in-class BCI market approval. Synchron competes in neurotechnology ahead of rivals like Neuralink, which had not reached human trials by late 2022. The company continued fundraising, completing a Series D of $200 million in November 2025 led by Double Point Ventures, with total raised reaching $325 million.
Jun 2021Series BKhosla Ventures (lead); ID8 Investments; Arani Bose; Subversive Capital; Thomas Reardon; Forepont Capital Partners; General Advance; Neurotechnology Investors; University of Melbourne; METIS innovative; Shanda Group; re.Mind Capital$40M$140MSynchron is a brain-computer interface company developing minimally invasive implantable BCI technology via the jugular vein, known as Stentrode, to enable paralyzed patients to control digital devices through thought. The company had commenced clinical trials in Australia with four patients enrolled by June 2021 and planned U.S. pivotal trials following FDA breakthrough device designation. Headquartered in New York with offices in Silicon Valley and R&D in Melbourne, Australia, Synchron positions itself as a leader in endovascular BCI, differentiating from surgical alternatives. On June 3, 2021, Synchron raised $40 million in a Series B round led by Khosla Ventures, with participation from Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, re.Mind Capital, Arani Bose, Thomas Reardon, Neurotechnology Investors, METIS innovative, and University of Melbourne, bringing total funding to $59 million including government support. The proceeds funded U.S. clinical trials for paralysis treatment and development of neurointerventional sensing and stimulating products for conditions like Parkinson’s, epilepsy, depression, and hypertension.
Apr 2017Series ANeurotechnology Investors (lead); DARPA$10M-Synchron is a neurotechnology company developing endovascular brain-computer interface (BCI) technology for treating brain and nervous system disorders. The company was founded in 2016 by Nicholas Opie and Thomas Oxley. Synchron's implantable neural interface aims to provide minimally invasive neuromodulation solutions. In April 2017, Synchron raised $10 million in its Series A funding round led by Neurotechnology Investors, with DARPA also participating. The funding was intended to develop and refine their BCI technology. Valuation details for this round were not publicly disclosed. Synchron has continued to advance with subsequent rounds, including a $40 million Series B in June 2021 led by Khosla Ventures to fund U.S. clinical trials, a $75 million Series C in December 2022 led by ARCH Venture Partners to scale operations, and later rounds totaling over $300 million raised to date.

Who has invested in Synchron?

22 investors have backed Synchron across its funding rounds, including Neurotechnology Investors, Khosla Ventures, ARCH Venture Partners, METIS innovative, K5 Global and Qatar Investment Authority.

Lead investors include Double Point Ventures, ARCH Venture Partners, Khosla Ventures and Neurotechnology Investors.


Synchron Investors

Investors in Synchron by funding rounds participated
InvestorHQRoundsRoleFirst check
Neurotechnology InvestorsUnited StatesSan Francisco, CA3LeadApr 2017
Khosla VenturesUnited StatesSan Francisco, CA2LeadJun 2021
METIS innovativeUnited StatesMiami, FL2ParticipantJun 2021
ARCH Venture PartnersUnited StatesChicago, IL2LeadDec 2022
K5 GlobalUnited StatesSan Francisco, CA1ParticipantNov 2025
ID8 InvestmentsUnited StatesNew York City, NY1ParticipantJun 2021
Double Point VenturesUnited StatesWest Palm Beach, FL1LeadNov 2025
Qatar Investment AuthorityQatarQatar1ParticipantNov 2025
Arani BoseUnited StatesNew York City, NY1ParticipantJun 2021
Subversive CapitalUnited StatesNew York City, NY1ParticipantJun 2021
Thomas ReardonUnited StatesProvidence, RI1ParticipantJun 2021
Forepont Capital PartnersUnited StatesNew York City, NY1ParticipantJun 2021
T.Rx CapitalUnited StatesSan Francisco, CA1ParticipantNov 2025

This data is available for Pro users. Sign up to see all 22 Synchron investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Synchron

Synchron has acquired 1 company to date.

Last acquisition by Synchron was on February 1st 2024. Synchron acquired Acquandas for undisclosed valuation.


Latest Acquisitions by Synchron

Acquandas
Description
Acquandas is a supplier of thin-film platinum temperature sensors and humidity probes for medical devices and laboratory equipment. Based in the Netherlands, it produces sensors with tolerances under 0.1 degrees Celsius for ventilators and incubators. The company serves OEMs in Europe and North America from an ISO 13485-certified facility.
HQ CountryGermany
HQ City
Kiel
Deal Date1 Feb 2024
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Synchron acquisitions and their M&A valuation multiples.

Start Free Trial

Synchron Competitors

Synchron competitors include listed companies like Shanghai Haohai and LifeTech Scientific, and private ones like ZD Medtech, Ankon Medical Technologies, AcuityMD and BenevolentAI.

Public and private companies comparable to Synchron
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
ZD MedtechChinaShanghaiPrivate--$900M-
Shanghai HaohaiChinaChinaPublicly listed$365M$59M$889M1.8x
Ankon Medical TechnologiesChinaWuhanPrivate--$870M-
AcuityMDUnited StatesBoston, MAPrivate--$955M-
BenevolentAIUnited KingdomLondonPrivate$10M-$1B100.0x
LifeTech ScientificChinaChinaPublicly listed$204M$37M$771M-

Synchron Public Comps

Synchron is still privately-owned, but its public comps include Shanghai Haohai, MedicalSystem Technology, Mani Inc., Bioventus, CeriBell, InMode, Kuros Biosciences, Advanced Medical Solutions Group, Anteris Technologies US and SI-BONE.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Shanghai Haohai$365M$59M1.7x1.8x10.6x10.1x
MedicalSystem Technology$45M$12M18.9x15.6x70.7x62.9x
Mani Inc.$193M$60M4.0x3.6x12.9x9.7x
Bioventus$568M$99M2.0x1.9x11.4x9.4x
CeriBell$89M($50M)9.6x7.9x(17.0x)(14.2x)
InMode$370M$86M0.9x0.9x4.0x4.4x
Kuros Biosciences$146M$9M5.7x4.4x96.7x35.1x
Advanced Medical Solutions Group$307M$59M3.0x2.9x15.7x12.9x

This data is available for Pro users. Sign up to see all Synchron competitors and their valuation data.

Start Free Trial

Common questions about Synchron

When was Synchron founded?Synchron was founded in 2016.
Where is Synchron headquartered?Synchron is headquartered in New York City, NY, United States.
Is Synchron publicly listed?No, Synchron is a private, VC-backed company.
What is Synchron's valuation?Synchron was last valued at $900M in its Series D in November 2025.
How much funding has Synchron raised?Synchron has raised $325M across 4 funding rounds.
What was Synchron's last funding round?Synchron's last funding round was a $200M Series D in November 2025, led by Double Point Ventures.
Who are Synchron's investors?Synchron's investors include Neurotechnology Investors, Khosla Ventures, METIS innovative, ARCH Venture Partners, K5 Global, ID8 Investments, Double Point Ventures, Qatar Investment Authority, Arani Bose, Subversive Capital and 12 others.
Which companies are comparable to Synchron?Companies comparable to Synchron include ZD Medtech, Shanghai Haohai, Ankon Medical Technologies, AcuityMD, BenevolentAI and LifeTech Scientific.
How many companies has Synchron acquired?Synchron has acquired 1 company, including Acquandas.

See companies similar to Synchron

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial